1-1 of 1
Douglas A Jacobstein, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

An Open-Label, Dose Escalation, Multi-Center Phase 1 Study of PRLX 93936, an Agent Synthetically Active Against the Activated Ras Pathway, in the Treatment of Relapsed or Relapsed and Refractory Multiple Myeloma

Peter M Voorhees, MD, Robert L. Schlossman, MD, Cristina J Gasparetto, MD, Jesus G. Berdeja, MD, John Morris, MD, Douglas A Jacobstein, MD, Kenneth C. Anderson, MD, Constantine S Mitsiades, MD PhD, Jacob P. Laubach, MD, Paul G. Richardson
Journal: Blood
Blood (2014) 124 (21): 2140.
https://doi.org/10.1182/blood.V124.21.2140.2140
Published: 2014